Navigation Links
Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
Date:10/31/2007

n of action is believed to relate to diminished affinity for the natriuretic peptide clearance receptor and increased resistance to the enzyme neutral endopeptidase, both pathways for clearance of endogenous natriuretic peptides. In animal models, PL-3994 was able to induce diuresis (excretion of fluids) with a limited decrease in blood pressure. The compound is well absorbed by the subcutaneous route of administration.

About Congestive Heart Failure (CHF)

Currently in the U.S., CHF affects nearly 5 million people and 550,000 new cases of CHF will be diagnosed this year. Despite the treatment of CHF with multiple drugs, almost all CHF patients will experience at least one episode of acute CHF that requires treatment with intravenous medications in the hospital. Congestive heart failure has tremendous human and financial costs. Annual medical expenditures for CHF are estimated to be $28.8 billion.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. The Company's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. The Company currently has collaborations with AstraZeneca and the Mallinckrodt division of Covidien. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Statements about the Company's future expectations, including statements about its development programs, the significance of the results of clinical trials, the conduct of future clinical trials, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, a
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
3. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Electrocardiogram (ECG) Devices - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... reach US$330 million by 2016. The North ... the global market share while Europe ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... RICHMOND, Va., April 18, 2011 BB&T Capital Markets ... LLC, d/b/a Dr. Comfort, the leading developer, manufacturer and ... products, in its sale to DJO Global, an international ... health and pain management based in Vista, Calif. Dr. ...
... GAITHERSBURG, Md., April 18, 2011 Sigma-Tau Pharmaceuticals, ... received approval from the U.S. Food and Drug ... in the oncology medicine ONCASPAR® (pegaspargase).  ONCASPAR is ... is a key component in the treatment of ...
Cached Medicine Technology:BB&T Advises Dr. Comfort on Its Sale to DJO Global in Transaction Valued at $254.6 Million 2Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient 2Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient 3Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient 4
(Date:12/17/2014)... Alan Mozes HealthDay ... With the holiday party season fast approaching, a new study ... make DUI arrests have fewer drunk drivers on their roads. ... laws more vigilantly are better able to deter inebriated revelers ... "Hardly any new laws are being passed regarding drinking and ...
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic alliance ... Ocean Avenue has secured exclusive benefit to the strategic ... JM Ocean Avenue is a direct sales company ... and JM International, with partial ownership coming from JM ... , “After nearly 2 decades of servicing the industry ...
(Date:12/15/2014)... December 15, 2014 Health Dialog, ... announced today that it has received Patient Oriented ... (NCQA) for its Disease Management (DM) Programs for ... (COPD), coronary heart disease and diabetes. This marks ... for Health Dialog’s Disease Management (DM) Programs, reaffirming ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device regulatory consulting ... South America, Europe, the Middle East, Asia and Australia, ... 2015 Medical Device Industry Survey. Each year, Emergo conducts ... market trends as well as regulatory and operational concerns ... , Overall prospects for medical device ...
(Date:12/15/2014)... La Jolla, Calif. (PRWEB) December 15, 2014 ... Roasters made the Coffee Review “Top 30 Coffees of 2014.” ... number two, and their Guji Zone Ethiopia at number 10. ... list twice. , Coffee Review’s selection is ranked on ... The Sumatra Ulos Batak scored 96 out of 100, and ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... Popular ,Out of the Closet, Thrift Store, Non-profit,AHF Pharmacy, ... Make a Difference, Grand Opening Event to Include ... This Saturday, February,2nd at 10:00 a.m., AIDS Healthcare ... Pharmacy, with a grand opening event to include,a ribbon-cutting ...
... enthused about Part D,s success, but critics say problems ... The three-year-old Medicare Part D drug program is seeing ... for the program fall, U.S. health officials announced Thursday. ... lower than originally projections, enrollment continues to rise and ...
... of the novel drug romiplostim (Nplate) show that it ... thrombocytopenic purpura (ITP), a hematologic disorder that can cause ... 3 trial results for the drug, which duplicates the ... General Hospital (MGH) investigator, in the February 2 issue ...
... International Associates, Inc.,administrator for the HealthShares(TM) Indexes, a ... Funds, today announced,that effective at the opening of ... BIM) will replace GYRUS GROUP PLC (GYG LN),in ... Companies that are included in The HealthShares(TM) ...
... in Karmanos Cancer Institute,s Annual Dinner, May 17, ... Karmanos,Cancer Institute will upgrade its nurse paging system, ... according to Nick Karmanos, vice,president of development for ... "As Lead Sponsor for our 26th Annual Dinner ...
... differences between nonprofit, for-profit banks should be explained , , ... tell pregnant patients considering umbilical cord blood banking about ... blood banks, new guidelines state. , The American College ... Opinion in the February issue of Obstetrics & ...
Cached Medicine News:Health News:West Hollywood: AHF Hosts Grand Opening of HIV/AIDS Pharmacy that Benefits AIDS Patients Worldwide 2Health News:West Hollywood: AHF Hosts Grand Opening of HIV/AIDS Pharmacy that Benefits AIDS Patients Worldwide 3Health News:Medicare's Drug Program Enrollment Up, Costs Down 2Health News:Medicare's Drug Program Enrollment Up, Costs Down 3Health News:Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder 2Health News:Ford Motor Company Fund Continues Longtime Support to Cancer Care 2Health News:Docs Should Tell All About Cord Blood Banks 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: